What question did this study set out to answer?

The central aim is to explore effective management strategies for tumor lysis syndrome in high-risk lung cancer patients.

April 10, 2026Open Access

Tumor Lysis Syndrome in Lung Cancer Patients: A Review of the Literature

Key Points

The central aim is to explore effective management strategies for tumor lysis syndrome in high-risk lung cancer patients.
Review of existing literature on tumor lysis syndrome and management in lung cancer patients.
Evaluation of urate-lowering therapy and hydration protocols for preventing TLS.
Consideration of the role of rasburicase in treating TLS.
Proactive therapy and hydration may significantly reduce mortality in high-risk lung cancer patients experiencing TLS.
Multicenter studies could lead to refined diagnostic criteria and guidelines for risk assessment.
Improved prophylactic measures may benefit other patients with solid tumors.

Abstract

For patients with high-risk lung cancer (LC), proactive initiation of urate-lowering therapy and hydration along with rasburicase and continued hydration for those who develop tumor lysis syndrome (TLS) may reduce mortality. Further multicenter studies may influence diagnostic criteria, risk assessment, and prophylactic guidelines for TLS to better account for high-risk LC and other solid tumor patients.

Tumor Lysis Syndrome in Lung Cancer Patients: A Review of the Literature

Key Points

Abstract

Cite This Study